NEW YORK, Sept. 9, 2016
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm,
reminds purchasers of Tokai Pharmaceuticals, Inc. securities
(NASDAQ: TKAI) from June 24, 2015
through July 25, 2016, both dates
inclusive (the "Class Period") of the important September 30, 2016 lead plaintiff deadline in the
class action. The lawsuit seeks to recover damages for Tokai
Pharmaceuticals investors under the federal securities laws.
To join the Tokai Pharmaceuticals class action, go to the firm's
website at http://rosenlegal.com/cases-928.html or call
Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or
email pkim@rosenlegal.com or kchan@rosenlegal.com for more
information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants
issued false and misleading statements to investors and/or failed
to disclose that: (1) there were significant structural problems
with the trial design for Tokai Pharmaceuticals' pivotal Phase 3
galeterone study, ARMOR3-SV; (2) in turn, ARMOR3-SV was unlikely to
succeed in meeting its primary endpoint; (3) consequently,
commercialization of galeterone was less likely and/or imminent
than Tokai Pharmaceuticals had led investors to believe; and (4) as
a result, defendants' statements about Tokai Pharmaceuticals'
business and operations were false and misleading and/or lacked a
reasonable basis. When the true details entered the market, the
lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
September 30, 2016. A lead plaintiff
is a representative party acting on behalf of other class members
in directing the litigation. If you wish to join the litigation, go
to the firm's website at http://rosenlegal.com/cases-928.html for
more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at
866-767-3653 or via email at pkim@rosenlegal.com or
kchan@rosenlegal.com. Attorney Advertising. Prior results do
not guarantee a similar outcome.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm or on Twitter:
https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/investor-alert-rosen-law-firm-reminds-tokai-pharmaceuticals-inc-investors-of-important-september-30-deadline-in-class-action---tkai-300325588.html
SOURCE Rosen Law Firm, P.A.